Bristol-Myers Squibb
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
19% more first-time investments, than exits
New positions opened: 194 | Existing positions closed: 163
6% more capital invested
Capital invested by funds: $91.5B [Q4 2024] → $96.9B (+$5.44B) [Q1 2025]
2% more call options, than puts
Call options by funds: $1.73B | Put options by funds: $1.7B
0.32% less ownership
Funds ownership: 78.48% [Q4 2024] → 78.15% (-0.32%) [Q1 2025]
3% less repeat investments, than reductions
Existing positions increased: 935 | Existing positions reduced: 964
1% less funds holding
Funds holding: 2,442 [Q4 2024] → 2,417 (-25) [Q1 2025]
10% less funds holding in top 10
Funds holding in top 10: 39 [Q4 2024] → 35 (-4) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$53
7%
upside
Avg. target
$58
17%
upside
High target
$68
37%
upside
6 analyst ratings
2 positive
33%
4 neutral
67%
0 negative
0%
Wells Fargo Mohit Bansal | 7%upside $53 | Equal-Weight Maintained | 28 Apr 2025 |
Cantor Fitzgerald Carter Gould | 11%upside $55 | Neutral Reiterated | 23 Apr 2025 |
Jefferies Akash Tewari | 37%upside $68 | Buy Maintained | 23 Apr 2025 |
Piper Sandler David Amsellem | 31%upside $65 | Overweight Initiated | 22 Apr 2025 |
UBS Trung Huynh | 9%upside $54 | Neutral Maintained | 11 Apr 2025 |
Financial journalist opinion
Based on 47 articles about BMY published over the past 30 days
Positive
Zacks Investment Research
1 day ago
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
Positive
Zacks Investment Research
2 days ago
BMY Reports Positive Data on Sotyktu From Arthritis Study
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
Positive
Seeking Alpha
2 days ago
Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends
The Dividend Harvesting Portfolio hit a new all-time high, delivering a 26.95% return and $2,310.77 in forward annual dividend income. I continue to diversify across ETFs, REITs, CEFs, BDCs, and equities, with a focus on mitigating downside risk and growing recurring income. Recent additions include ARE, PDI, and MSTY, all chosen for their income potential and upside as rate cuts approach.
Neutral
Business Wire
3 days ago
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025.
Neutral
Business Wire
3 days ago
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025.
Neutral
Seeking Alpha
3 days ago
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization Officer Christopher S. Boerner - CEO & Chairman Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider All right.
Positive
Zacks Investment Research
3 days ago
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Neutral
Business Wire
4 days ago
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EULAR--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu.
Neutral
GlobeNewsWire
4 days ago
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.
Positive
Seeking Alpha
4 days ago
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
Charts implemented using Lightweight Charts™